AstraZeneca joins stepped-up antibiotic R&D action with FOB Synthesis deal

AstraZeneca ($AZN) notched an antibiotics research deal with a licensing/option set-up with FOB Synthesis, covering combinations of the two companies' experimental drugs. AstraZeneca plans to test its own beta lactamase inhibitor alongside the smaller company's carbapenem drugs FSI-1671 and FSI-1686. Report

Suggested Articles

Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.

Private equity firm, in exclusive talks with Sanofi, says it'll invest to pump up Zentiva into an "independent European generics leader."

With suitor Takeda circling Shire, the Dublin-based target has pulled off a deal of its own.